Five Prime Therapeutics, Inc. Announces the Exercise of the Underwriters' Over-Allotment Option

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime) announced today that the underwriters of its initial public offering have exercised their over-allotment option in full to purchase an additional 720,000 shares of common stock from Five Prime at the initial public offering price of $13.00 per share. With the exercise of the underwriters' over-allotment option, the total number of shares sold in the offering was 5,520,000 shares, resulting in aggregate gross proceeds of $71.8 million, before underwriting discounts, commissions and expenses. All of such shares were sold by Five Prime.

Help employers find you! Check out all the jobs and post your resume.

Back to news